Mavatar recruits Nordic Life Science profile Ulrika Nyberg

Report this content

Takes key role in global expansion phase

Mavatar, a pioneer in AI- and data-driven precision medicine, is accelerating its momentum following last week’s early commercial launch of the research platform Mavatar Discovery. The company has appointed Ulrika Nyberg as Head of Strategic Partnerships, with a mandate to drive strategic collaborations as Mavatar enters its next growth phase. This recruitment marks the beginning of a broader expansion in the Nordics and a strengthened international presence.

Ulrika Nyberg is a well-known figure in the Nordic Life Science community. She brings over 20 years of experience from senior roles in industry media, as well as extensive work in communications and policy within both medtech and the pharmaceutical industry. With her unique combination of strategic networking skills and deep industry expertise, she is expected to play a central role in Mavatar’s continued establishment on the global market.

I have a constant drive and curiosity for next-generation tech solutions, which makes it especially exciting to be part of Mavatar’s journey. I look forward to contributing to the acceleration of AI adoption in precision medicine, both in the Nordics and globally. It feels both meaningful and inspiring,” says Ulrika Nyberg.

Mavatar CEO Johan Juhlin comments:
We are very pleased to welcome Ulrika to Mavatar. Her extensive experience and broad network within Life Science make her a key part of our efforts to build strong partnerships and to further establish Mavatar in both the Nordic and global markets.”

Ulrika Nyberg will assume her role on October 1.

 

 

 

 

Linda Wakeham
Chife Marketing & Communication Officer
linda.wakeham@mavatar.com

Mavatar is a global specialist in AI-driven precision medicine solutions for all diseases. Built on over 20 years of scientific research, Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework powers two flagship platforms: Mavatar Discovery for accelerating disease and drug research, and Mavatar Precision for delivering personalized treatment recommendations in clinical care. By creating digital twins of both patients and diseases, Mavatar enables data-driven decisions that improve treatment outcomes, optimize clinical trials, and reduce healthcare waste. Headquartered in Stockholm, Sweden, Mavatar is driving the future of truly personalized, scalable healthcare across all disease areas. mavatar.com

Tags:

Subscribe

Media

Media

Quotes

We are very pleased to welcome Ulrika to Mavatar. Her extensive experience and broad network within Life Science make her a key part of our efforts to build strong partnerships and to further establish Mavatar in both the Nordic and global markets
Johan Juhlin, CEO & Co-founder Mavatar